Pharmaceuticals

SHKK

SHKK released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue USD 38.99 M, actual EPS USD 0.0099

SHKK to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

SHKK released FY2025 Q4 earnings on March 27 After-Market (BJT), actual revenue USD 43.93 M, actual EPS USD 0

SHKK released FY2025 Annual Earnings on March 27 After-Market (BJT), actual revenue USD 158.73 M, actual EPS USD 0.007

SHKK FY2025 Annual Earnings Release Scheduled for March 28, 2026 After-Market BJT

SHKK released FY2025 9 Months earnings on October 30 After-Market (BJT), actual revenue USD 114.86M, actual EPS USD 0.0073

SHKK released FY2025 Q3 earnings on October 30 After-Market BJT, actual revenue USD 39.6 M, actual EPS USD 0.0005

SHKK to Release FY2025 Q3 Earnings on October 31 After-Market (BJT)

SHKK released FY2025 Semi-Annual earnings on August 22 During-Market (BJT), actual revenue USD 75.25 M, actual EPS USD 0.0067

SHKK released FY2025 Q2 earnings on August 22 During-Market (BJT), actual revenue USD 38.14 M, actual EPS USD 0.0022

SHKK to Release FY2025 Semi-Annual Earnings on August 23, 2025 (BJT)

SHKK released FY2024 earnings on April 29 After-Market (BJT), actual revenue USD 151.94 M, actual EPS USD 0.0194

SHKK released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue USD 37.12 M, actual EPS USD 0.0045

SHKK released FY2024 Q4 earnings on April 29 After-Market BJT, actual revenue USD 47.81 M, actual EPS USD 0.0002

SHKK to Release FY2025 Q1 Earnings Report on April 30 After-Market BJT

SHKK to Release FY2024 Annual Earnings on April 30 After-Market BJT

SHKK released FY2024 9 Months Earnings on October 29 After-Market (BJT), actual revenue USD 104 M, actual EPS USD 0.0197

SHKK released FY2024 Q3 earnings on October 29 After-Market BJT, actual revenue USD 36.43 M, actual EPS USD 0.002

Shanghai Kai Kai Industry to Announce Q3 2024 Earnings on Oct 30, 2024

SHKK released FY2024 Semi-Annual earnings on August 16 After-Market (BJT), actual revenue USD 67.58 M, actual EPS USD 0.0176

The global stigmasterol-rich plant sterols market is projected to reach USD 1,281.42 million by 2036, driven by rising cardiovascular health awareness and demand for functional foods. The market is transitioning towards standardized formulations and regulatory support, with significant growth in applications across food, nutraceuticals, and pharmaceuticals. Key growth regions include India, Germany, and China, with a forecast CAGR of 3.8% from 2026 to 2036. The market is bolstered by increasing consumer preference for plant-based wellness solutions and regulatory approvals for health claims.

MorningStar

Stigmasterol-Rich Plant Sterols Market to Reach USD 1,281.42 Million by 2036 as Cardiovascular Health Awareness and Functional Food Demand Expand Globally

Senate Minority Leader Chuck Schumer criticized Donald Trump's recent trip to China, labeling it a 'photo op' that failed to address key issues such as fentanyl, Taiwan, U.S. manufacturing, and AI. Schumer stated that Trump returned with 'nothing to show for it' and highlighted concerns over the lack of action on fentanyl flow, protections for U.S. manufacturers, and doubts regarding U.S. commitment to Taiwan.

benzinga_article

NVIDIA

Alibaba

BABA-W

TENCENT

Tencent

NVIDIA Corporation

BABA-WR

Alibaba HK SDR 5to1

TENCENT-R

Tencent HK SDR 10to1

Tencent Holdings Limited

Chuck Schumer Slams Trump China Trip As 'Photo Op' With Xi Jinping, Says Visit Delivers 'Nothing' On Fentanyl, Taiwan And AI

The bleeding disorder testing market is projected to grow from USD 109.2 billion in 2025 to USD 234.6 billion by 2036, with a CAGR of 7.2%. This growth is driven by rising demand for performance-grade diagnostic solutions, increased hospital procurement, and a focus on regulatory compliance. Key segments include reagents and consumables, with hemophilia A being the leading indication. Major growth regions include China, India, Germany, France, and the United States, as healthcare institutions prioritize reliable diagnostic systems.

Siemens Healthineers AG

Roche

Thermo Fisher Scentific

Abbott Laboratories

Horiba , Ltd.

Pfizer

Baxter

ROCHE HOLDINGS AG

FMI Reveals Bleeding Disorder Testing Market USD 117.1 Billion in 2026 to USD 234.6 Billion by 2036 Driven by Expanding Demand for Performance-Grade Diagnostic Solutions

Chinese rehabilitation robot manufacturers are expanding into international markets, leveraging technological advancements despite facing regulatory challenges. Experts highlight the rapid development of robot technology and the importance of partnerships for market entry. The global rehabilitation equipment market is projected to grow significantly, driven by an aging population and increasing health issues. Companies are adapting their strategies to meet varying market receptiveness, particularly in Europe and the U.S.

Yicai

Chinese Rehab Robot Makers Leverage Tech Advantages to Expand Overseas, Experts Say

600272

900943

SHKK released its 2025 semi-annual report, reporting an operating income of 543 million yuan, a year-on-year increase of 10.95%. The net profit attributable to the parent company was 11.801 million yuan, a year-on-year decrease of 61.94%; the net profit after deducting non-recurring gains and losses was 3.0084 million yuan, a year-on-year decrease of 8.67%. The basic earnings per share were 0.049 yuan

Zhitong

SHKK released its performance for the first half of the year, with a net profit attributable to the parent company of 11.801 million yuan, a year-on-year decrease of 61.94%

According to the Zhitong Finance APP, SHKK announced that the company intends to transfer its 11.11% equity in Nanjing Tianshi Software Technology Co., Ltd. (referred to as "Nanjing Tianshi") through public listing at the Shanghai United Assets and Equity Exchange. The minimum price for this public listing transfer will not be less than 17.4123 million yuan. After the transfer is completed, the company will no longer hold any equity in Nanjing Tianshi

SHKK plans to publicly list and transfer 11.11% equity of Nanjing Tianshi

SHKK expects its net profit in the first half of 2025 to decrease by 61.62% to 63.08% year-on-year, with a projected net profit attributable to the owners of the parent company of between 11.45 million yuan and 11.90 million yuan, a decrease of 19.109 million yuan to 19.559 million yuan. The net profit after deducting non-recurring gains and losses is expected to be between 2.70 million yuan and 3.20 million yuan, a year-on-year decrease of 2.85% to 18.03%

SHKK: Expected net profit in the first half of 2025 to decrease by 61.62% to 63.08% year-on-year

SHKK released its Q1 2025 performance report, with operating revenue of 270 million yuan, a year-on-year increase of 15.05%. The net profit attributable to the parent company was 7.9784 million yuan, a year-on-year decrease of 65.7%; the net profit after deducting non-recurring gains and losses was 1.475 million yuan, a year-on-year increase of 527.72%. The basic earnings per share were 0.033 yuan/share

SHKK released its first-quarter performance, with a net profit attributable to the parent company of 7.9784 million yuan, a year-on-year decrease of 65.7%

SHKK announced that it will adhere to the "big health" transformation and development strategy in 2025, focusing on the development of three major business segments: pharmaceutical health, medical health, and health care. The company plans to promote industrial integration through three major engines: "brand +", "capital +", and "internet +". At the same time, the clothing segment will deepen quality improvement and efficiency enhancement to improve profitability

SHKK: Adhering to the "Big Health" transformation and development strategy in 2025

According to the Zhitong Finance APP, SHKK announced a stock price fluctuation notice stating that the company's A-shares have experienced 4 trading limit ups in the last 5 trading days from December 11, 2024, with a cumulative closing price increase deviation exceeding 50% and a turnover rate exceeding 80%. Recently, the trading price of the company's stock has increased significantly, and the turnover rate is high, which may pose a risk of irrational speculation. Investors are advised to pay attention to secondary market trading risks, make rational decisions, and be aware of investment risks

SHKK: Recent stock price has increased significantly, which may pose a risk of irrational speculation

SHKK(900943.SH)